Arbutus' AB-729 shows encouraging results in chronic hepatitis B

• Arbutus Biopharma (NASDAQ:ABUS) announces updated clinical data from an ongoing Phase 1a/1b clinical trial (AB-729-001) with AB-729, its GalNAc delivered RNAi compound in chronic hepatitis B infection.
• Single-doses of AB-729 studied to date, 60 mg, 90 mg and 180 mg, resulted in comparable mean HBsAg declines at week 12, followed by a sustained plateau phase.
• 60 mg of AB-729 dosed every 4 weeks resulted in continuous declines in HBsAg, reaching a mean of –1.44 log10 IU/ML at week 16.
• Data beyond week 16 demonstrate further declines in HBsAg with no plateau seen to date.
• AB-729 also resulted in meaningful decreases in both HBV RNA and HBcrAg and was generally safe and well tolerated.
• The data was presented at The Liver Meeting Digital Experience, The American Association for the Study of Liver Diseases Meeting.
• Arbutus will hold conference call and webcast on November 16, at 8:00 am ET to provide an update on AB-729.
• https://seekingalpha.com/news/3636408-arbutus-abminus-729-shows-encouraging-results-in-chronic-hepatitis-b